Current Headlines

21. NIH Funds Studies To Improve Type 2 And Prediabetes Treatment
    5/22/2013

    The National Institutes of Health is looking for volunteers to take part in one of three clinical trials to improve and preserve the production of insulin in people with prediabetes or recently diagnosed type 2 diabetes.

22. WHO Publishes Draft On Revised Process Validation Guideline: Validation Life-Cycle Required
    5/22/2013

    The WHO has published a proposal for the revision of its supplementary guideline on GMP validation (Annex 7: non-sterile process validation).

23. Mayo Clinic Forms Joint Venture With Cancer Genetics
    5/22/2013

    Mayo Clinic ("Mayo") and Cancer Genetics Inc. recently launched OncoSpire Genomics ("OncoSpire"), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

24. Global Vision's Text Comparison Software Docu-Proof Recognized By The EMA For Regulatory Submissions
    5/21/2013

    Global Vision, the industry leader in the development of automated proofreading solutions, recently announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribution methods of medicinal products.

25. Drawing Closer To Alzheimer’s Magic Bullet?
    5/21/2013

    Imagine a pharmaceutical prevention, treatment or even cure for Alzheimer’s disease. By Jonathan Riggs

26. Liquidia Technologies Announces Extension Of Collaboration With PATH To Develop Next Generation Pneumococcal Vaccine
    5/21/2013

    Liquidia Technologies recently announced that its collaborative agreement with PATH, a global health nonprofit organization, has been extended.

27. Transgene Announces Its Invesment In ElsaLys Biotech, A New Antibody Company Created By Former Executives
    5/21/2013

    Regulatory News: Transgene SA , a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, recently announced its participation to the first private equity round of Elsalys Biotech, a newly created therapeutic monoclonal antibody player.

28. Study Shows Whole-Cell Vaccine Was More Effective Than Acellular Vaccine During California Pertussis Outbreak
    5/20/2013

    Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.

29. Novozymes Biopharma’s Recombinant Human Albumin Helps Innovative Dry Eye Therapy Move Into Clinical Trials
    5/20/2013

    Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, recently announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

30. The Start-Up Elsalys Biotech, A New Player In The Therapeutic Monoclonal Antibody Arena, Announces The First Round Of Financing With Transgene And Sofimac Partners
    5/17/2013

    ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.